We aim ultimately to measure the entire proteome in order to identify the most specific biomarkers and to generate deeper insights into the pathophysiological mechanisms underlying human disease or associated with therapeutic response. Measuring an additional 3,500 proteins on the 11K Assay is anticipated to provide new biomarkers that we were not able to measure previously, which could help to develop diagnostics with higher accuracy."
Towia Libermann, PhD
Associate Professor of Medicine
Director, BIDMC Genomics, Proteomics,
Bioinformatics, and Systems Biology Center And DF/HCC Cancer Proteomics Core
Div. of Interdisciplinary Medicine and Biotechnology
Beth Israel Deaconess Medical Center